This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights include: Mallinckrodt, Dell, American Axle, Daqo and General Motors
by Zacks Equity Research
Zacks.com featured highlights include: Mallinckrodt, Dell, American Axle, Daqo and General Motors
6 Low Price-to-Book Stocks for Value Investors
by Zacks Equity Research
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Mylan (MYL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when the company reports Q4 results.
Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects
by Zacks Equity Research
Continued price erosion and intensifying competition in generic drug market is negatively impacting the top line of industry participants. However, stabilizing outlook is encouraging.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the fourth quarter.
What's in the Cards for Bausch Health (BHC) Q4 Earnings?
by Zacks Equity Research
Investors are looking forward to Salix and Bausch+Lomb's performance, and other pipeline updates when Bausch (BHC) reports Q4 results on Feb 20.
MNK vs. AMPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MNK vs. AMPH: Which Stock Is the Better Value Option?
Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?
by Zacks Equity Research
Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.
Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Tilray (TLRY) reports fourth-quarter results.
Exelixis (EXEL) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Exelixis' (EXEL) fourth-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.
6 Low Price-to-Book Value Stocks to Buy in February
by Zacks Equity Research
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Why Mallinckrodt (MNK) Could Beat Earnings Estimates Again
by Zacks Equity Research
Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3
by Zacks Equity Research
Dr. Reddy's earnings and sales rise year over year in the third-quarter of fiscal 2019.
Mylan's Generic Version of Advair Diskus Wins FDA Approval
by Zacks Equity Research
Mylan (MYL) secures an FDA approval for the first generic version of blockbuster COPD drug, Advair Diskus.
MNK vs. AMPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MNK vs. AMPH: Which Stock Is the Better Value Option?
Zacks.com featured expert Kevin Matras highlights: Mallinckrodt Public, Dell Technologies, American Axle & Manufacturing, Magna International and General Motors
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Mallinckrodt Public, Dell Technologies, American Axle & Manufacturing, Magna International and General Motors
6 Promising Price-to-Book Value Stocks With Solid Prospects
by Zacks Equity Research
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
MNK vs. AMPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MNK vs. AMPH: Which Stock Is the Better Value Option?
Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility
by Zacks Equity Research
Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.
Cara (CARA) Up on IDMC's Recommendation to Continue Trial
by Zacks Equity Research
Cara (CARA) gains after IDMC recommended the late-stage trial on lead drug, Korsuva, to continue without any modifications.
Heron Gains on Priority Review Designation for Pain Drug
by Zacks Equity Research
Heron (HRTX) soars after the FDA accepted the company's NDA for pain drug, HTX-011, and granted Priority Review designation to the application.
Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III
by Zacks Equity Research
Mallinckrodt (MNK) and partner NPXe Limited enrol the first patient in the phase III study on xenon gas for inhalation (XENEX) for Post Cardiac Arrest Syndrome (PCAS).
Mallinckrodt's Roxicodone Reformulation Gets CRL From FDA
by Zacks Equity Research
Mallinckrodt (MNK) receives complete response letter from the FDA related to its regulatory application seeking approval for abuse-deterrent reformulation of opioid painkiller, Roxicodone.
Mallinckrodt (MNK) to Separate Generics & Branded Businesses
by Zacks Equity Research
Mallinckrodt (MNK) announces plans to split its generic and branded businesses into two different companies.